{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.55","value":"-4.57"},{"groupId":"OG001","spread":"1.87","value":"-8.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Global health status"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.29","value":"-3.76"},{"groupId":"OG001","spread":"1.59","value":"-7.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Functional scale: Physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.73","value":"-4.87"},{"groupId":"OG001","spread":"2.12","value":"-9.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"title":"Functional scale: Role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.38","value":"2.38"},{"groupId":"OG001","spread":"1.70","value":"-2.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Functional scale: Emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.29","value":"-3.16"},{"groupId":"OG001","spread":"1.58","value":"-2.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Functional scale: Cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.61","value":"-4.62"},{"groupId":"OG001","spread":"1.97","value":"-4.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Functional scale: Social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.45","value":"5.01"},{"groupId":"OG001","spread":"1.78","value":"7.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Symptom scale: Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.35","value":"2.81"},{"groupId":"OG001","spread":"1.64","value":"6.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Symptom scale: Nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.82","value":"-0.47"},{"groupId":"OG001","spread":"2.21","value":"4.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Symptom scale: Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.70","value":"5.21"},{"groupId":"OG001","spread":"2.10","value":"5.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Symptom scale: Dyspnoea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.86","value":"-0.04"},{"groupId":"OG001","spread":"2.27","value":"3.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Symptom scale: Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.85","value":"2.06"},{"groupId":"OG001","spread":"2.23","value":"6.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Symptom scale: Appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.59","value":"-0.15"},{"groupId":"OG001","spread":"1.92","value":"3.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Symptom scale: Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.66","value":"4.14"},{"groupId":"OG001","spread":"1.99","value":"2.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Symptom scale: Diarrhoea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.60","value":"0.34"},{"groupId":"OG001","spread":"1.96","value":"2.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"title":"Symptom scale: Financial difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 110 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. LS Mean value of changing from baseline to short follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\\*Visit and baseline.","dispersionType":"Standard Error","groups":[{"description":"Abemaciclib 150 mg administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG000","title":"Abemaciclib + Fulvestrant"},{"description":"Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug with baseline and post-baseline EORTC QLQ-C30 data at short term follow up for each EORTC QLQ-C30 items.","reportingStatus":"POSTED","timeFrame":"Baseline, Short Term Follow Up (Up To 31 Months)","title":"Change From Baseline to Short Term Follow up in Quality of Life Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"units on a scale"}